Fortekor Flavour 20 mg Tablets for Dogs

Dogs:
Rare
(1 to 10 animals / 10,000 animals treated):
Diarrhoea, Vomiting,
Anorexia, Fatigue
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Elevated creatinine
,
Incoordination
In dogs with chronic kidney disease, the product may increase plasma creatinine concentrations
at the start of therapy. A moderate increase in plasma creatinine concentrations following
administration of ACE inhibitors is compatible with the reduction in glomerular hypertension
induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence
of other signs.
In double-blind clinical trials in dogs with congestive heart failure, the veterinary medicinal
product was well tolerated with an incidence of adverse reactions lower than observed in
placebo-treated dogs.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also section 16 of the package
leaflet for respective contact details.

Revised: June 2025
AN: 00325/2025